Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Table 3

Comparison of changes in the anthropometric, clinical, and biochemical parameters during the study period between the intervention and control groups.

	Control group	Intervention group	P value
Body weight	0.02±0.64	0.21±0.61	0.220
BMI	−0.01±0.89	0.12±0.43	0.092
Systolic blood pressure	1.37±4.98	−7.58±8.04	<0.0001*
Diastolic blood pressure	2.96±14.48	1.61±6.37	0.638
Fasting glucose	9.89±15.72	−34.93±29.53	<0.0001*
Insulin	−0.27±3.15	−4.82±4.83	<0.0001*
HbA1c	0.01±0.67	−1.20±1.56	<0.0001*
HOMA-IR	0.22±1.50	−2.69±2.79	<0.0001*
HOMA-β	−2.74±2.84	−9.16±12.27	0.549
Triglyceride	−11.56±36.71	−17.81±39.87	0.591
Total cholesterol	6.69±40.68	−11.33±35.24	0.121
HDL-cholesterol	−2.4±6.26	4.75±5.83	0.001*
LDL-cholesterol	9.22±12.88	−11.33±30.65	0.006*
SGOT	−2.34±9.96	0.83±7.90	0.174
SGPT	2.20±9.09	1.16±7.03	0.619
GGT	−0.89±7.88	1.25±8.97	0.329
ALP	20.03±28.15	5.35±32.86	0.069
Creatinine	0.05±0.28	−0.06±0.21	0.062

Data is presented as means ± SD. ^∗𝑃<0.05 versus control group. HOMA-β: homeostasis model of assessment for beta cell function; HbA1c: Hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein; TG: triglyceride; SGOT: serum glutamate oxaloacetate transaminase; SGPT: serum glutamate pyruvate transaminase; GGT: gamma-glutamyltransferase; ALP: alkaline phosphatase.